RWM
RYTM icon

Rialto Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Rialto Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$108 – 1791
2025
Q4 		$108 Buy
+1
New +$106 ﹤0.01% 1628

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Rialto Wealth Management's RYTM Position: Q1 2026 in Review

Rialto Wealth Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1 share — an estimated $108 sold.

Rialto Wealth Management first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $108 in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Rialto Wealth Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rialto Wealth Management sold 1 Rhythm Pharmaceuticals share in Q1 2026, an estimated $108.
  • Rialto Wealth Management first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Rialto Wealth Management's Rhythm Pharmaceuticals position peaked at $108 in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.